Transformative Approaches to Biomarker Assessment and Clinical Profiles in Pulmonary Hypertension Patients
DOI:
https://doi.org/10.31661/gmj.vi.4132Abstract
Background: Pulmonary hypertension (PH) is a progressive disorder marked by elevated pulmonary arterial pressure, leading to right heart failure and high mortality. Emerging evidence links metabolic disturbances, renal dysfunction, and molecular dysregulation to PH pathogenesis. This study aimed to investigate biochemical and molecular biomarkers associated with PH, focusing on renal, metabolic, and vascular parameters. Materials and Methods: A hospital-based case–control study was conducted at Al-Sadr Teaching Hospital, Iraq, from January to June 2024. Sixty-two PH patients and 30 age- and sex-matched healthy controls were recruited. Fasting venous blood samples were analyzed for urea, creatinine, glucose, insulin, uric acid, troponin I, homocysteine, and KCNK3. Insulin resistance (IR) was estimated using HOMA-IR. Comparisons between groups were performed using independent t-tests, correlations via Pearson’s coefficient, and diagnostic performance assessed using ROC curve analysis. Results: PH patients exhibited significantly elevated urea, creatinine, glucose, insulin, uric acid, homocysteine, and IR (P < 0.05) and reduced KCNK3 levels (P = 0.006) compared to controls. ROC analysis showed IR (AUC 0.903), homocysteine (AUC 0.762), and insulin (AUC 0.808) as effective discriminators of PH, whereas KCNK3 had limited diagnostic accuracy (AUC 0.350). Correlation analysis demonstrated positive associations between homocysteine and insulin/glucose, while KCNK3 inversely correlated with renal and metabolic parameters. Subgroup analysis indicated higher urea and glucose in male patients (P < 0.05). Conclusion: PH is associated with systemic metabolic dysregulation, renal impairment, and molecular alterations, including reduced KCNK3 and elevated homocysteine. Insulin resistance and homocysteine may serve as potential non-invasive biomarkers, highlighting the need for integrated biochemical and molecular assessment in PH management.
References
Mocumbi A, Humbert M, Saxena A, Jing ZC, Sliwa K, Thienemann F, Archer SL, Stewart S. Pulmonary hypertension. Nature reviews Disease primers. 2024 Jan 4;10(1):1.
https://doi.org/10.1038/s41572-023-00486-7
PMid:38177157
Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European respiratory journal. 2019 Jan 24;53(1).
https://doi.org/10.1183/13993003.01913-2018
PMid:30545968 PMCid:PMC6351336
Maron BA. Revised definition of pulmonary hypertension and approach to management: a clinical primer. Journal of the American Heart Association. 2023 Apr 18;12(8):e029024.
https://doi.org/10.1161/JAHA.122.029024
PMid:37026538 PMCid:PMC10227272
Ratwatte S, Playford D, Strange G, Celermajer DS, Stewart S. Prevalence and prognostic significance of pulmonary hypertension in adults with left ventricular diastolic dysfunction. Open Heart. 2024 Dec 3;11(2).
https://doi.org/10.1136/openhrt-2024-003049
PMid:39627022 PMCid:PMC11624820
Walther CP, Nambi V, Hanania NA, Navaneethan SD. Diagnosis and management of pulmonary hypertension in patients with CKD. American Journal of Kidney Diseases. 2020 Jun 1;75(6):935-45.
https://doi.org/10.1053/j.ajkd.2019.12.005
PMid:32199709 PMCid:PMC7247937
Ishizu T, Hayashi Y, Tokushige N, Omura J. Real-world diagnostic landscape and incidence of pulmonary hypertension in adult congenital heart disease patients using administrative claims data in Japan. Current Medical Research and Opinion. 2024 Apr 2;40(4):555-65.
https://doi.org/10.1080/03007995.2024.2323632
PMid:38420663
Leary PJ, Lindstrom M, Johnson CO, Emmons-Bell S, Rich S, Corris PA, DuBrock HM, Ventetuolo CE, Abate YH, Abdelmasseh M, Aboagye RG. Global, regional, and national burden of pulmonary arterial hypertension, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet Respiratory Medicine. 2025 Jan 1;13(1):69-79.
Anderson JJ, Lau EM. Pulmonary Hypertension Definition, Classification, and Epidemiology in Asia. JACC. Asia. 2022;2(5):538-546.
https://doi.org/10.1016/j.jacasi.2022.04.008
PMid:36624795 PMCid:PMC9823284
Mocumbi AO, Thienemann F, Sliwa K. A global perspective on the epidemiology of pulmonary hypertension. The Canadian journal of cardiology. 2015;31(4):375-81.
https://doi.org/10.1016/j.cjca.2015.01.030
PMid:25840090
Yang Y, Zeng Z, Yang Q, Wang H, Zhang H, Yan W, Wang P, Wang C, Su Z, Thangaraju P, Safi SZ. The Challenge in Burden of Pulmonary Arterial Hypertension: A Perspective From the Global Burden of Disease Study. MedComm. 2025 May;6(5):e70175.
https://doi.org/10.1002/mco2.70175
PMid:40276646 PMCid:PMC12019876
Klok FA, Couturaud F, Delcroix M, Humbert M. Diagnosis of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. European Respiratory Journal. 2020 Jun 25;55(6).
https://doi.org/10.1183/13993003.00189-2020
PMid:32184319
Szewczuk K, Dzikowska-Diduch O, Gołębiowski M. The use of imaging in the diagnosis and treatment of thromboembolic pulmonary hypertension. Cardiology Journal. 2025;32(4):392-406.
https://doi.org/10.5603/cj.102716
PMid:40439542 PMCid:PMC12410944
Ley L, Grimminger F, Richter M, Tello K, Ghofrani A, Bandorski D. The early detection of pulmonary hypertension. Deutsches Ärzteblatt International. 2023 Dec 1;120(48):823.
https://doi.org/10.3238/arztebl.m2023.0222
PMid:37882345 PMCid:PMC10853922
Kovacs G, Dumitrescu D, Barner A, Greiner S, Grünig E, Hager A, Köhler T, Kozlik-Feldmann R, Kruck I, Lammers AE, Mereles D. Definition, clinical classification and initial diagnosis of pulmonary hypertension: Updated recommendations from the Cologne Consensus Conference 2018. International journal of cardiology. 2018 Dec 1;272:11-9.
https://doi.org/10.1016/j.ijcard.2018.08.083
PMid:30219257
Pawar SG, Khan N, Salam A, Joshi M, Saravanan PB, Pandey S. The association of Pulmonary Hypertension and right ventricular systolic function-updates in diagnosis and treatment. Disease-a-Month. 2024 Feb 1;70(2):101635.
https://doi.org/10.1016/j.disamonth.2023.101635
PMid:37734967
Johns CS, Wild JM, Rajaram S, Swift AJ, Kiely DG. Current and emerging imaging techniques in the diagnosis and assessment of pulmonary hypertension. Expert Review of Respiratory Medicine. 2018 Feb 1;12(2):145-60.
https://doi.org/10.1080/17476348.2018.1420478
PMid:29261337
Kovacs G, Reiter G, Reiter U, Rienmüller R, Peacock A, Olschewski H. The emerging role of magnetic resonance imaging in the diagnosis and management of pulmonary hypertension. Respiration. 2008 Nov 1;76(4):458-70.
https://doi.org/10.1159/000158548
PMid:19018164
Nistal MS. Pulmonary hypertension: The contribution of MDCT to the diagnosis of its different types. Radiología (English Edition). 2010 Jan 1;52(6):500-12.
https://doi.org/10.1016/S2173-5107(10)70024-0
Ribeuz HL, Willer AS, Chevalier B, Sancho M, Masson B, Eyries M, Jung V, Guerrera IC, Dutheil M, Jekmek KE, Laubry L. Role of KCNK3 dysfunction in dasatinib-associated pulmonary arterial hypertension and endothelial cell dysfunction. American journal of respiratory cell and molecular biology. 2024 Jul;71(1):95-109.
https://doi.org/10.1165/rcmb.2023-0185OC
PMid:38546978
Le Ribeuz H, Dumont F, Ruellou G, Lambert M, Balliau T, Quatredeniers M, Girerd B, Cohen-Kaminsky S, Mercier O, Yen-Nicolaÿ S, Humbert M. Proteomic analysis of KCNK3 loss of expression identified dysregulated pathways in pulmonary vascular cells. International Journal of Molecular Sciences. 2020 Oct 7;21(19):7400.
https://doi.org/10.3390/ijms21197400
PMid:33036472 PMCid:PMC7582549
Lambert M, Capuano V, Boet A, Tesson L, Bertero T, Nakhleh MK, Remy S, Anegon I, Pechoux C, Hautefort A, Rucker-Martin C. Characterization of Kcnk3-mutated rat, a novel model of pulmonary hypertension. Circulation research. 2019 Sep 13;125(7):678-95.
https://doi.org/10.1161/CIRCRESAHA.119.314793
PMid:31347976
Saint‐Martin Willer A, Santos‐Gomes J, Adão R, Brás‐Silva C, Eyries M, Pérez‐Vizcaino F, Capuano V, Montani D, Antigny F. Physiological and pathophysiological roles of the KCNK3 potassium channel in the pulmonary circulation and the heart. The Journal of Physiology. 2023 Sep;601(17):3717-37.
https://doi.org/10.1113/JP284936
PMid:37477289
Wang MT, Chi PL, Cheng CC, Huang WC, Chen LW. Application of homocysteine as a non-invasive and effort-free measurements for risk assessment of patients with pulmonary hypertension. Cardiology Journal. 2024;31(2):285-99.
https://doi.org/10.5603/cj.92813
PMid:37772357 PMCid:PMC11076026
Sanli C, Oguz D, Olgunturk R, Tunaoglu FS, Kula S, Pasaoglu H, Gulbahar O, Cevik A. Elevated homocysteine and asymmetric dimethyl arginine levels in pulmonary hypertension associated with congenital heart disease. Pediatric cardiology. 2012 Dec;33(8):1323-31.
https://doi.org/10.1007/s00246-012-0321-9
PMid:22526220
Arroliga AC, Sandur S, Jacobsen DW, Tewari S, Mustafa M, Mascha EJ, Robinson K. Association between hyperhomocysteinemia and primary pulmonary hypertension. Respiratory medicine. 2003 Jul 1;97(7):825-9.
https://doi.org/10.1016/S0954-6111(03)00038-6
PMid:12854633
Zhang S, Gao L, Li S, Luo M, Chen L, Xi Q, Zhao Z, Zhao Q, Yang T, Zeng Q, Li X. Association of non-insulin-based insulin resistance indices with disease severity and adverse outcome in idiopathic pulmonary arterial hypertension: a multi-center cohort study. Cardiovascular Diabetology. 2024 May 3;23(1):154.
https://doi.org/10.1186/s12933-024-02236-9
PMid:38702735 PMCid:PMC11069206
Gao G, Chen A, Yan Y, Sagor MI, Lin W, Lin H, Lian G, Xie L, Luo L. Role of insulin signaling dysregulation in pulmonary vascular remodeling in rats with monocrotaline-induced pulmonary arterial hypertension. Frontiers in Cardiovascular Medicine. 2025 Mar 24;12:1543319.
https://doi.org/10.3389/fcvm.2025.1543319
PMid:40196172 PMCid:PMC11973325
Zamanian RT, Hansmann G, Snook S, Lilienfeld D, Rappaport KM, Reaven GM, Rabinovitch M, Doyle RL. Insulin resistance in pulmonary arterial hypertension. European respiratory journal. 2009 Jan 30;33(2):318-24.
https://doi.org/10.1183/09031936.00000508
PMid:19047320 PMCid:PMC2785883
Boiko O, Rodionova V, Shevchenko L. Features of Kidney Function in Patients With Comorbidity of Arterial Hypertension and Chronic Obstructive Pulmonary Disease. Cureus. 2022 Nov 23;14(11):e31828.
https://doi.org/10.7759/cureus.31828
PMid:36579215 PMCid:PMC9787688
Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Noordegraaf AV, Beghetti M, Ghofrani A. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Polish Heart Journal (Kardiologia Polska). 2015;73(12):1127-206.
https://doi.org/10.5603/KP.2015.0242
PMid:26727670
Risan TZ, Ali BM. Study the effect of amphetamine on neurotransmitter factors in abusers individuals. InAIP Conference Proceedings 2024 Mar 8 (Vol. 3092, No. 1, p. 030005). AIP Publishing LLC.
https://doi.org/10.1063/5.0200213
Metra M, Nodari S, Parrinello G, Specchia C, Brentana L, Rocca P, Fracassi F, Bordonali T, Milani P, Danesi R, Verzura G. The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT‐proBNP and cardiac troponin‐T. European journal of heart failure. 2007 Aug;9(8):776-86.
https://doi.org/10.1016/j.ejheart.2007.05.007
PMid:17573240
Mehta KS, Shirkande AK, Bhurke SP, Pajai AE, Swami RS, Jadhav SN. Pulmonary hypertension in various stages of chronic kidney disease in Indian patients. Indian Journal of Nephrology. 2019 Mar 1;29(2):95-101.
https://doi.org/10.4103/ijn.IJN_407_17
PMid:30983749 PMCid:PMC6440332
Uyar M. Impact of Pulmonary Hypertension on Renal Functions in Obstructive Sleep Apnea Syndrome. Southern Medical Journal. 2023 Jan;116(1):26-32.
https://doi.org/10.14423/SMJ.0000000000001494
PMid:36578114
Keller K, Beule J, Balzer JO, Dippold W. Renal function as a cofactor for risk stratification and short-term outcome in acute pulmonary embolism. Experimental gerontology. 2017 Dec 15;100:11-6.
https://doi.org/10.1016/j.exger.2017.10.007
PMid:29030164
Zhou Y, Chen M, Zheng J, Shui X, He Y, Luo H, Lei W. Insights into the relationship between serum uric acid and pulmonary hypertension. Molecular Medicine Reports. 2023 Nov 21;29(1):10.
https://doi.org/10.3892/mmr.2023.13133
PMid:37997855 PMCid:PMC10704563
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Galen Medical Journal

This work is licensed under a Creative Commons Attribution 4.0 International License.





